Heart 2006;92:149-151
EDITORIAL
Natriuretic peptides as a prognostic marker and therapeutic target in heart failure
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
Correspondence to:
Dr Gary A Wright
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; gary.gawright{at}gmail.com
Natriuretic peptides may have an increasing role in assisting clinicians to target treatment in patients with chronic heart failure
Abbreviations: ACE, angiotensin converting enzyme; ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CHF, chronic heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MADIT, multicenter automatic defibrillator implantation trial; NYHA, New York Heart Association; Val-HeFT, valsartan heart failure trial
Keywords: B-type natriuretic peptide; BNP; prognosis; heart failure; therapy
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
